Ignite Creation Date:
2024-05-05 @ 11:41 PM
Last Modification Date:
2024-10-26 @ 10:38 AM
Study NCT ID:
NCT01392235
Status:
COMPLETED
Last Update Posted:
2019-01-22
First Post:
2011-07-03
Brief Title:
Famitinib in Treating Patients With Recurrent andor Metastatic Nasopharyngeal Carcinoma NPC
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
A Single-arm Open Multicenter Phase II Study of Famitinib as Third Line Treatment in Patients With Recurrent andor Metastatic Nasopharyngeal Carcinoma NPC
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Famitinib is a tyrosin-inhibitor agent targeting at c-Kit VEGFR2 PDGFR VEGFR3 Flt1 and Flt3 Phase I study has shown that the drugs toxicity is manageable
PURPOSE This phase II trial is studying how well famitinib works in treating patients with recurrent andor metastatic NPC
PURPOSE This phase II trial is studying how well famitinib works in treating patients with recurrent andor metastatic NPC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None